ER-PHARMA
ActiveSummary
ER-PHARMA has been active since 2022 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €55,819 and a net result of €13,994. Equity is growing by about 33% per year across the filed financial years. Its solvency ranks better than 73% of 9,617 sector peers (NACE 82, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
29-06
NBB filing
Annual accounts filed
financial year 2025 · micro format
2025
22-08
NBB filing
Annual accounts filed
financial year 2024 · micro format · 22 days late
2024
31-12
Financial
Weakest financial yearnet €13,629 ▼48.9%
Net result drops to €13,629, the lowest in the series; recovery starts the following year.
24-09
Gazette deed
Registered officeRegistered-office move2 facts ▸
Gazette deed
Registered office
Registered-office move2 facts ▸
- Board meeting, 08-08-2024
- Registered-office move, Sint-Antoniusstraat 8a,8500 Kortrijk
29-08
NBB filing
Annual accounts filed
financial year 2023 · micro format · 29 days late
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
1 of 2 deeds read
About the unread acts
Of the 2 Belgian Official Gazette deeds we know for this company, 1 has been read. The other one has not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.